CA2782472C - Method of treating scars and beta-catenin-mediated disorders - Google Patents

Method of treating scars and beta-catenin-mediated disorders Download PDF

Info

Publication number
CA2782472C
CA2782472C CA2782472A CA2782472A CA2782472C CA 2782472 C CA2782472 C CA 2782472C CA 2782472 A CA2782472 A CA 2782472A CA 2782472 A CA2782472 A CA 2782472A CA 2782472 C CA2782472 C CA 2782472C
Authority
CA
Canada
Prior art keywords
nefopam
scar
catenin
use according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2782472A
Other languages
English (en)
French (fr)
Other versions
CA2782472A1 (en
Inventor
Benjamin A. Alman
Helen Hong
Raymond Poon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children
Original Assignee
Hospital for Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44166687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2782472(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospital for Sick Children filed Critical Hospital for Sick Children
Publication of CA2782472A1 publication Critical patent/CA2782472A1/en
Application granted granted Critical
Publication of CA2782472C publication Critical patent/CA2782472C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
CA2782472A 2009-12-15 2010-12-15 Method of treating scars and beta-catenin-mediated disorders Active CA2782472C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28663309P 2009-12-15 2009-12-15
US61/286,633 2009-12-15
PCT/CA2010/002014 WO2011072394A1 (en) 2009-12-15 2010-12-15 METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS

Publications (2)

Publication Number Publication Date
CA2782472A1 CA2782472A1 (en) 2011-06-23
CA2782472C true CA2782472C (en) 2019-04-16

Family

ID=44166687

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2782472A Active CA2782472C (en) 2009-12-15 2010-12-15 Method of treating scars and beta-catenin-mediated disorders

Country Status (10)

Country Link
US (4) US8957107B2 (enExample)
EP (1) EP2512468B1 (enExample)
JP (1) JP5792185B2 (enExample)
KR (1) KR101753439B1 (enExample)
CN (2) CN102781442B (enExample)
BR (1) BR112012014471A2 (enExample)
CA (1) CA2782472C (enExample)
DK (1) DK2512468T3 (enExample)
ES (1) ES2594900T3 (enExample)
WO (1) WO2011072394A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781442B (zh) * 2009-12-15 2016-02-17 儿童医院 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11266637B2 (en) * 2018-06-01 2022-03-08 Iterion Therapeutics, Inc. Formulations of tegavivint and related compounds
CN110638780A (zh) * 2019-09-11 2020-01-03 华益药业科技(安徽)有限公司 一种盐酸奈福泮片及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0213869D0 (en) * 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
PT1572672E (pt) 2002-12-20 2008-10-02 Sosei R & D Ltd Benzoxazocinas e sua utilização como inibidores de reabsorção de monoamina
US20060019940A1 (en) 2002-12-20 2006-01-26 Baxter Andrew D Novel benzoxazocines and their therapeutic use
GB0330049D0 (en) 2003-12-24 2004-02-04 Arakis Ltd The treatment of neuropathic pain conditions
WO2005103019A1 (en) 2004-04-21 2005-11-03 Sosei R&D Ltd. Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors
GB2413322A (en) 2004-04-21 2005-10-26 Arakis Ltd Nefopam analogues
CN1569004A (zh) * 2004-05-13 2005-01-26 南昌弘益科技有限公司 盐酸奈福泮滴丸及其制备方法
FR2880275B1 (fr) 2005-01-06 2007-04-13 Biocodex Utilisation de composes pharmacologiques pour la prevention ou le traitement de la tolerance aigue aux morphiniques
GB0506835D0 (en) 2005-04-04 2005-05-11 Arakis Ltd Therapeutic use of nefopam
GB0515703D0 (en) 2005-07-29 2005-09-07 Arakis Ltd Therapeutic use of nefopam
CN101002756A (zh) 2007-01-19 2007-07-25 陶燃 盐酸奈福泮的透皮贴片制剂
GB0721013D0 (en) 2007-10-25 2007-12-05 Sosei R & D Ltd New Salts
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
GB2461874B (en) 2008-07-14 2012-11-21 Caltec Ltd Separation system and method
FR2940911B1 (fr) * 2009-01-13 2012-09-21 Philippe Perovitch Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques
CN102781442B (zh) * 2009-12-15 2016-02-17 儿童医院 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法

Also Published As

Publication number Publication date
WO2011072394A1 (en) 2011-06-23
EP2512468B1 (en) 2016-08-24
US8957107B2 (en) 2015-02-17
HK1174565A1 (zh) 2013-06-14
CN105687185A (zh) 2016-06-22
US20150105363A1 (en) 2015-04-16
US9566263B2 (en) 2017-02-14
CN102781442A (zh) 2012-11-14
HK1224224A1 (zh) 2017-08-18
DK2512468T3 (en) 2016-11-14
CN105687185B (zh) 2019-07-09
CA2782472A1 (en) 2011-06-23
JP5792185B2 (ja) 2015-10-07
KR101753439B1 (ko) 2017-07-19
US20170172980A1 (en) 2017-06-22
ES2594900T3 (es) 2016-12-23
US10722493B2 (en) 2020-07-28
KR20120110117A (ko) 2012-10-09
BR112012014471A2 (pt) 2017-06-06
US20170281594A1 (en) 2017-10-05
EP2512468A4 (en) 2013-08-07
JP2013513625A (ja) 2013-04-22
CN102781442B (zh) 2016-02-17
EP2512468A1 (en) 2012-10-24
US20120294928A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
EP2512468B1 (en) METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS
KR101823275B1 (ko) 전립선 암종의 치료를 위한 병용 요법
WO2016040877A1 (en) Human dosing of phosphatase inhibitor
Mihailidou et al. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models
WO2020062951A1 (zh) 化合物及其用途
EP3579840B1 (en) Treatment of cancer and inhibition of metastasis
CN111281869B (zh) 褪黑素在制备用于治疗和辅助治疗骨肉瘤的药物中的应用
JP2025529453A (ja) 皺皮および皺の外観を軽減するために低分子の化学化合物を使用する方法
EP4357345A1 (en) Cly series compound, preparation method therefor and use thereof in preparation of drugs
JP2015534942A (ja) Ｃｂｐ／カテニン阻害剤を用いる過剰増殖性及び前がん性皮膚病の治療
AU2017242155B2 (en) Stable pharmaceutical compositions for topical administration and uses thereof
WO2020028745A1 (en) Methods for reducing abnormal scar formation
KR20240164549A (ko) 암 치료를 위한 metap2 억제제를 포함하는 조합
HK1224224B (en) Method of treating aggressive fibromatoses and betacatenin-mediated disorders using nefopam compounds
HK1174565B (en) Method of treating scars and ss-catenin-mediated disorders using nefopam compounds
KR102459443B1 (ko) Ac_774를 포함하는 흑색종 예방 또는 치료용 조성물
EP3070092B1 (en) 3-phenyl-thiazolo[3,2-a]benzimidazole derivatives as aldehyde dehydrogenase 1 (aldh-1) modulators for the treatment of breast cancer or leukemia, and for manipulating cultured aldh-1 positive breast cancer or leukemia cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151208

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251020

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251021

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260804